Medicare Drug Price Negotiation & Optimal Cancer Dosing: Reducing Costs & Toxicity

A New Path to Lowering Cancer Drug Costs: CMS Negotiations and Beyond

The escalating cost of cancer care in the United States has created a significant burden for patients and families, a phenomenon increasingly referred to as “financial toxicity.” For years, the U.S. Has consistently faced the highest prescription drug prices globally, and cancer medications are a major driver of this expense. Now, a new strategy is unfolding, with the Centers for Medicare & Medicaid Services (CMS) taking a more active role in negotiating drug prices – and there’s potential to go even further.

In 2022, Congress passed a law enabling CMS to negotiate maximum prices for select brand-name drugs, focusing on those without generic equivalents and representing the highest Medicare spending. This marked a significant shift in the landscape of pharmaceutical pricing. Initial results from the Medicare Drug Price Negotiation Program (MDPNP) show substantial savings, with an average discount of 47% secured on five oncology drugs in the first two rounds of negotiations. This translates to an estimated $5.5 billion in annual savings, according to CMS figures reported in early 2026.

Expanding the List of Negotiated Drugs

The impact of these negotiations is set to expand. Just five weeks ago, CMS announced a new list of drugs subject to the MDPNP, including four additional oncology medications: Erleada, Kisqali, Lenvima, and Verzenio. If CMS achieves similar savings rates with these drugs, an additional $2.8 billion in annual savings could be realized. The most recent list signals a continued commitment to lowering drug costs for Medicare beneficiaries.

Beyond Negotiation: Addressing Excessive Dosing

However, price negotiation is only one piece of the puzzle. Federal law already empowers CMS to ensure that medical services and items – including drugs – are “reasonable and necessary.” While CMS covers all antineoplastic (anticancer) drugs under Medicare Part D, it currently doesn’t consistently limit coverage to dosages that align with this “reasonable and necessary” standard. A significant opportunity exists to reduce spending by addressing the practice of prescribing and reimbursing excessive doses of cancer drugs.

The Food and Drug Administration (FDA) currently approves cancer drugs based on safety and efficacy, often at the maximum tolerated dose (MTD). This MTD, while ensuring the drug works, frequently results in substantial side effects. But for many drugs, particularly those targeting specific molecular pathways, lower doses can achieve the same therapeutic benefit with fewer adverse effects. This concept is gaining traction within the oncology community, as highlighted by the FDA’s Project Optimus, which acknowledges that more isn’t always better.

The Case of Kisqali: A Dose Reduction Opportunity

Consider Kisqali, a drug approved in 2017 for advanced breast cancer at a dose of 600 mg daily. The FDA approval letter actually required Novartis, the drug’s manufacturer, to investigate a lower dosage due to safety concerns. A subsequent study comparing 600 mg and 400 mg daily demonstrated virtually identical outcomes in terms of survival and progression-free survival, with the lower dose exhibiting reduced toxicity according to research published recently. Despite this evidence, the FDA maintained the 600 mg dosage, citing the initial study’s endpoints. However, this doesn’t preclude CMS from determining that the higher dose isn’t “reasonable and necessary” under Medicare guidelines.

If CMS were to cover only the lower, equally effective dose of Kisqali, it could save an estimated one-third of the total cost, on top of any savings achieved through price negotiation. This isn’t an isolated case. Researchers at the Optimal Cancer Care Alliance have compiled a compendium of alternative dosage strategies for 90 patent-protected oral oncology drugs, identifying potential cost savings of up to 75% for five of the nine drugs currently undergoing price negotiation.

Understanding Financial Toxicity

The high cost of cancer treatment extends beyond the price of the drugs themselves. “Financial toxicity,” a term coined in 2013 to describe the financial hardship experienced by cancer patients, encompasses copayments, deductibles, and coinsurance. As noted in a 2019 article in Cancer Biology & Therapy, the economic burden of cancer care is increasingly falling on patients, with potentially catastrophic consequences for their health and quality of life. The problem isn’t new, but it’s worsening, with cancer survivors often reporting higher out-of-pocket spending than individuals without a cancer history as detailed by the National Cancer Institute.

The Impact of Side Effects on Overall Costs

Reducing excessive dosing isn’t just about lowering drug costs; it’s also about improving patient well-being and reducing the overall cost of care. Severe side effects from cancer treatment can significantly impact a patient’s quality of life, leading to fear of treatment and even discontinuation of therapy. These side effects can also necessitate additional medical interventions, further increasing costs. In some cases, the fear of treatment can even exceed the fear of the disease itself.

What’s Next: A Call for Collaboration

To further explore these issues, the Optimal Cancer Care Alliance is hosting a meeting, Novel Solutions to Address the Rising Cost of Oncology Drugs: Targeting the Demand Side, on March 4-5 at Georgetown Law in Washington, D.C. The conference aims to bring together policymakers, payers, prescribers, and patients to discuss strategies for optimizing cancer drug dosages and reducing healthcare spending.

Addressing the rising cost of cancer care requires a multifaceted approach. While CMS’s price negotiation efforts are a crucial step, focusing on the “demand side” – ensuring that drugs are prescribed and reimbursed at reasonable and necessary dosages – presents a significant opportunity to improve patient outcomes and reduce costs for both patients and taxpayers. A collaborative effort, grounded in evidence-based medicine and a commitment to patient well-being, is essential to navigate this complex challenge.